Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Last trade$441.44
Day change-$19.81 (-4.29%)
Day range$432.69 – $457.52
Volume862,521
Market cap$55.40B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$55.4B
Price / earnings
43.31×
Price / book
2.88×
Price / sales
0.38×
EV / sales
0.43×
EV / EBITDA
21.28×
Profitability
Earnings per share
$10.65
Return on assets
2.24%
Return on equity
6.66%
Dividend yield
0.78%
Liquidity and leverage
Debt / equity
0.74×
Current ratio
1.68×
Quick ratio
1.68×
Cash ratio
0.92×
Cash flow
Price / cash flow
21.82×
Price / free cash flow
28.42×
Free cash flow
$1.95B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HUM, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$40.87B
$39.65B
$32.38B
$32.25B
$32.39B
$32.11B
$28.92B
$29.05B
Cost of revenue
$35.37B
$33.71B
$28.72B
$27.99B
$27.57B
$26.54B
$25.38B
$25.12B
Gross profit
$5.5B
$5.94B
$3.66B
$4.26B
$4.82B
$5.58B
$3.54B
$3.93B
Selling, general and administrative
$3.98B
$4.02B
$4.44B
$4.09B
$3.55B
$3.38B
$4.17B
$3.34B
Research and development
—
—
—
—
—
—
—
—
Total operating expenses
$39.51B
$37.89B
$33.32B
$32.25B
$31.29B
$30.1B
$29.76B
$28.67B
Operating income
$1.36B
$1.75B
-$944M
-$1M
$1.1B
$2.01B
-$840M
$385M
Interest expense
-$197M
-$193M
-$146M
-$168M
-$157M
-$160M
-$164M
-$169M
Income before taxes
$952M
$1.6B
-$1.01B
$134M
$741M
$1.69B
-$862M
$651M
Income taxes
$238M
$395M
-$249M
-$86M
$179M
$406M
-$216M
$155M
Net income
$693M
$1.18B
-$776M
$194M
$543M
$1.24B
-$683M
$480M
Net income attributable to common shareholders
$694M
$1.19B
-$796M
$195M
$545M
$1.24B
-$693M
$480M
EBITDA
$1.55B
$1.95B
-$750M
$203M
$1.31B
$2.23B
-$600M
$628M
Basic earnings per share
$5.78
$9.85
-$6.61
$1.62
$4.52
$10.31
-$5.75
$3.99
Diluted earnings per share
$5.73
$9.83
-$6.58
$1.62
$4.51
$10.30
-$5.74
$3.98
Recent news
Company coverage with links to the original publishers.
Humana (HUM) is highlighted as a strong momentum pick with a Zacks Rank #1 (Strong Buy) rating and Momentum Style Score of A. The health insurer has outperformed its industry and the broader market, with shares up 89.78% over the past year compared to the S&P 500's 13.41% gain. Recent earnings estimate revisions have been positive, with 10 upward revisions and none downward over the past two months.
Invesco Pharmaceuticals ETF (PJP) delivered 36.1% one-year returns with concentrated pharma exposure, significantly outperforming Simplify Health Care ETF (PINK) at 22.7%. PINK offers lower expenses, broader healthcare diversification, and donates profits to breast cancer research, while PJP provides 20+ years of track record but carries sector concentration risk.
Humana Inc. has launched a new oncology care model in partnership with Evolent Health and American Oncology Network across eight states. The initiative streamlines prior authorization for qualifying practices, uses EHR analytics and provider scorecards to promote evidence-based cancer treatment, and aims to improve care coordination while reducing specialty care spending. HUM stock has rallied 82.2% over the past year but trades at a premium valuation of 29.08x forward P/E versus the industry average of 15.72x.
Humana (HUM) has been upgraded to Zacks Rank #1 (Strong Buy) due to upward revisions in earnings estimates. The company is expected to earn $9.36 per share for fiscal year 2026, with consensus estimates rising 4.9% over the past three months. The upgrade positions Humana in the top 5% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals.
The Invesco S&P 500 Pure Value ETF (RPV) is reviewed as a reasonable option for large cap value exposure with a 0.35% expense ratio and $1.79 billion in assets. The ETF has gained 20.23% year-to-date and 25.22% over the past year, with a medium risk profile. However, competitors like Vanguard Morningstar Value ETF (VTV) and Schwab U.S. Dividend Equity ETF (SCHD) offer lower expense ratios and significantly larger asset bases.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.885 per share
Declared
Oct 29, 2026
Ex-dividend
Dec 24, 2026
Pay date
Jan 29, 2027
Ex-dividend
Amount / share
Pay date
Type
Oct 30, 2026
$0.885
Nov 27, 2026
recurring
Jun 26, 2026
$0.885
Jul 31, 2026
recurring
Mar 27, 2026
$0.885
Apr 24, 2026
recurring
Dec 26, 2025
$0.885
Jan 30, 2026
recurring
Sep 26, 2025
$0.885
Oct 31, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.